Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 3330
Journal of Biotechnology & Biomaterials received 3330 citations as per Google Scholar report
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- ResearchBible
- China National Knowledge Infrastructure (CNKI)
- Access to Global Online Research in Agriculture (AGORA)
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Protein engineering applied to obtain biobetters of antitumor enzyme asparaginase
Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry
Gisele Monteiro, Costa I M, Costa-Silva T A, Effer B, Meira-Lima G, Biasoto H P, Silva C, Pessoa A and Rangel-Yagui C
University of Sao Paulo, Brazil
ScientificTracks Abstracts: J Biotechnol Biomater
Abstract
Asparaginase (ASNase), an enzyme biotechnologically produced by bacteria, is one of the most important compounds in polychemotherapy to treat acute lymphoblastic leukemia (ALL) in children. There are only three options available as medicine: native enzyme from Erwinia chrysanthemi (ErA) or extracted from Escherichia coli (EcA) and formulated as native or PEGylated (PEG-EcA). However, these options yet present some problems in patients, such as to elicit hypersensitivity and allergenic reactions, neurotoxicity, and hyperammonemia. Aiming to avoid some of these problems, our research group has developed several different mutant proteoforms, expressed in bacteria and yeast, in periplasmic or secreted to extracellular space; with improvement in specific activity, kinetic parameters and stability; different oligomerization states, glycosylated or not, through engineering of genes from E. coli, E. chrysanthemi and S. cerevisiae. We obtained mutants from E. coli ASNase more resistant to human proteases and less immunogenic. In relation to E. chrysanthemi enzyme, our mutants present higher asparaginase activity than the native form, with improved kcat. In addition, we obtained strains of Pichia pastoris that express glycosylated ASNases from bacteria. Last but noteworthy, we obtained P. pastoris and E. coli strains that express active ASNases from S. cerevisiae, an eukaryotic promising options to replace bacterial formulations.Biography
Gisele Monteiro has completed her PhD at the University of São Paulo in Molecular Biology. Currently, she is an Associate Professor of Pharmaceutical Biotechnology in the Faculty of Pharmaceutical Sciences (FCF/USP) and the Vice-Coordinator of the Graduate Course in Biochemical-Pharmaceutical Technology. She has published more than 20 papers in reputed journals and has been serving as an Associate Editor of Brazilian Journal of Microbiology. She received 10 scientific awards, national and international. Her main scientific interest is the study of antitumor drugs and the engineering of proteins used as biopharmaceuticals, such as asparaginase.
E-mail: smgisele@usp.br
